Group 1 - The core point of the article is that Zhongke Information (SZ 300678) held its 24th meeting of the fourth board of directors on October 29, 2025, to review the proposal regarding the implementation details of total wage management [1] - For the first half of 2025, Zhongke Information's revenue composition is as follows: tobacco accounts for 33.9%, on-site meetings for 22.96%, others for 21.09%, government for 12.51%, and oil for 9.55% [1] - As of the report, Zhongke Information has a market capitalization of 9.9 billion yuan [1] Group 2 - The A-share market has surpassed 4000 points, marking a significant resurgence after a decade of stagnation, with technology leading the market's transformation into a new "slow bull" pattern [1]

Financial Performance - The company's operating revenue for Q3 2025 was ¥52,196,387.10, a decrease of 21.71% compared to the same period last year[4] - The net profit attributable to shareholders for Q3 2025 was ¥745,806.94, down 37.86% year-on-year[4] - The basic earnings per share for Q3 2025 was ¥0.0025, reflecting a decline of 37.50% compared to the previous year[4] - Total operating revenue for the current period was ¥193,751,244.66, a decrease of 11.2% from ¥218,236,369.58 in the previous period[22] - Operating profit for the current period was ¥9,328,859.36, compared to ¥10,778,282.84 in the previous period, indicating a decline of 13.5%[22] - Net profit for the current period is 4,275,958.81, a decrease of 16.1% from 5,093,497.45 in the previous period[23] - Total comprehensive income for the current period is 4,275,958.81, a decrease of 16.1% from 5,093,497.45 in the previous period[23] - Basic and diluted earnings per share are both 0.0152, down from 0.0209 in the previous period[23] Assets and Liabilities - Total assets at the end of Q3 2025 reached ¥1,272,048,615.06, an increase of 6.64% from the end of the previous year[5] - The total assets increased to ¥1,272,048,615.06 from ¥1,192,790,641.91, representing a growth of 6.7%[21] - Current liabilities rose to ¥414,139,773.43, up from ¥321,279,947.23, marking an increase of 29%[21] - The total liabilities increased to ¥422,816,346.41 from ¥333,015,017.42, reflecting a growth of 27%[21] - The total equity attributable to shareholders decreased to ¥846,218,671.64 from ¥856,524,656.94, a decline of 1.9%[21] - Cash and cash equivalents decreased to ¥398,521,682.34 from ¥476,092,459.93, a reduction of 16.3%[20] Cash Flow - The company's net cash flow from operating activities showed a negative net amount of ¥48,672,019.52, an increase of 52.66% in outflow compared to the previous year[4] - Operating cash flow net amount is -48,672,019.52, an improvement from -102,812,910.72 in the previous period[26] - Investment activities generated a net cash flow of -4,008,444.66, compared to -75,727,937.82 in the previous period, indicating a significant reduction in cash outflow[26] - Cash flow from financing activities resulted in a net outflow of -24,541,484.15, compared to -2,701,147.46 in the previous period[27] - Cash and cash equivalents at the end of the period stand at 390,462,665.57, an increase from 310,737,485.51 in the previous period[27] Inventory and Prepayments - The company reported a significant increase in inventory, which rose by 131.66% to ¥212,030,334.74 due to increased costs of unfinished projects[9] - The company experienced a substantial increase in prepayments, which rose by 228.36% to ¥125,121,747.97, attributed to project progress[9] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 48,947[13] - The largest shareholder, China Academy of Sciences Holdings Co., Ltd., holds 90,477,651 shares, representing a significant portion of the company's equity[15] - The total number of shares held by the top 10 unrestricted shareholders amounts to 100,000,000 shares, indicating strong institutional support[15] - The company has a total of 10,837,361 restricted shares at the beginning of the period, with 5,729,463 shares released from restriction during the period[17] - The company plans to release 268,880 additional restricted shares, resulting in a total of 5,376,778 restricted shares remaining[17] - The company has not disclosed any significant changes in shareholder relationships among the top 10 shareholders[15] - The company has a total of 1,339,400 shares held by Jiangsu Bank Co., Ltd. under a flexible allocation mixed securities investment fund[15] - The company has a total of 1,872,900 shares held by Wu Zhiming, indicating individual investor interest[15] - The company has a total of 1,367,400 shares held by China Minsheng Bank Co., Ltd., reflecting institutional investment[15] - The company has a total of 1,359,950 shares held by Qianhai Life Insurance Co., Ltd., showcasing diversified investment sources[15] - The company has a total of 2,169,828 shares held by Shanghai Tongli Industrial Co., Ltd., indicating potential strategic partnerships[15] Other Income - The company reported a decrease in other income by 44.64% to ¥1,475,072.24, due to reduced government subsidies recognized during the reporting period[12] - The company reported an investment income of ¥12,002,006.20, up from ¥6,612,362.94, indicating an increase of 81.5%[22]

中科院成都信息技术股份有限公司2025年第三季度报告全文于 2025年10月30日在中国证监会指定的创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）上披露，敬请投资者查阅。 特此公告。 中科院成都信息技术股份有限公司 董事会 证券代码：300678 证券简称：中科信息 公告编号：2025-078 中科院成都信息技术股份有限公司 2025年第三季度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 2025 年 10 月 29 日 1 / 1 ...

中科院成都信息技术股份有限公司（以下简称"公司"）第四届董 事会第二十四次会议于 2025 年 10 月 17 日以电子邮件方式发出会议通 知，本次会议于 2025 年 10 月 29 日以联签方式召开。会议应参与表决 董事为 9 名，实际参与表决董事 9 名。会议由公司董事长史志明主持， 公司董事会秘书、财务负责人列席了会议。本次会议的召集、召开和表 决程序符合有关法律、行政法规、部门规章、规范性文件及公司章程的 规定。 证券代码：300678 证券简称：中科信息 公告编号：2025-077 中科院成都信息技术股份有限公司 第四届董事会第二十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、会议召开情况 二、会议审议情况 与会董事对《通知》所列之议案进行了审议并通过了如下事项： （一）审议通过《关于 2025 年第三季度报告的议案》 经审议，董事会认为公司《2025 年第三季度报告》的编制程序符合 法律法规和中国证监会的有关规定，报告内容真实、准确、完整地反映 了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 （二）审议通过 ...

Core Insights - The Chinese optogenetics industry has made significant progress, transitioning from a technology follower to a leader, with a market size projected at approximately 5.276 billion yuan in 2024, reflecting a year-on-year growth of 9.10% [1][11] - Domestic research teams have achieved breakthroughs in the development of photosensitive proteins, gene delivery systems, and optical equipment, enhancing the efficiency and precision of optogenetics applications [1][11] - Despite advancements, existing optogenetic tools still face limitations, such as large control modules, poor tissue penetration, off-target effects, and optical toxicity, necessitating ongoing optimization [1][11] Industry Overview - Optogenetics combines optical and genetic techniques to control cell activity by expressing light-sensitive ion channels, pumps, or enzymes in target cells [2] - The basic principle involves inserting opsin genes into target neurons, allowing them to respond to specific wavelengths of light, thereby regulating ionic flow and neuronal activity [2] Industry Development History - The Chinese optogenetics industry has evolved through three main phases: early exploration and technology foundation (2004-2010), technological breakthroughs and clinical application exploration (2011-2020), and accelerated clinical translation and industrialization (2021-present) [4] - Key milestones include the first successful retinal treatment in 2016 and the development of the REDMAP system in 2023 [4] Industry Value Chain - The upstream of the optogenetics industry includes photosensitive proteins, gene delivery systems, raw materials, hardware systems, and auxiliary technologies [6] - The midstream focuses on optogenetics technology services, product research and development, while the downstream applications span neuroscience, cross-disciplinary fields, ophthalmology, neurology, cardiac diseases, and metabolic disorders [6] Market Size - The optogenetics market in China is expected to reach approximately 5.276 billion yuan in 2024, with a growth rate of 9.10% year-on-year [11] - Technological advancements, such as the REDMAP light switch developed by East China Normal University, have contributed to this market expansion [11] Industry Trends 1. **Innovative Technological Breakthroughs**: The industry is driven by technological innovation, facilitating rapid translation from laboratory to clinical applications, exemplified by the REDMAP light switch and ZM-02 gene therapy [14][16] 2. **Policy Support and Capital Acceleration**: National policies supporting innovative drugs and dynamic adjustments to medical insurance directories are stimulating the commercialization of optogenetic therapies [16] 3. **Cross-Disciplinary Applications**: Optogenetics is expanding beyond neuroscience into fields like tumor treatment, metabolic diseases, and mental health, fostering multi-disciplinary integration [17]

Core Viewpoint - Zhongke Information announced the resignation of independent directors Li Zhishu and Cao Dejun, who have served since August 29, 2019, marking the end of their six-year term [2] Group 1 - The board of directors received written resignation reports from independent directors Li Zhishu and Cao Dejun [2] - Both directors applied to resign from their positions on the fourth board of directors and related committees [2] - After their resignation, they will no longer hold any positions within the company [2]

中科院成都信息技术股份有限公司 关于独立董事任期届满的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 中科院成都信息技术股份有限公司(以下简称"公司")董事会于近 日收到公司独立董事李志蜀先生、曹德骏先生的书面辞职报告。李志蜀 先生、曹德骏先生自 2019 年 8 月 29 日以来连续担任公司独立董事已届 满六年，根据《上市公司独立董事管理办法》关于上市公司独立董事连 续任职年限的有关规定，李志蜀先生、曹德骏先生申请辞去公司第四届 董事会独立董事职务及董事会各专门委员会相关职务，辞职后不再担任 公司任何职务。 证券代码：300678 证券简称：中科信息 公告编号：2025-076 2 / 2 鉴于李志蜀先生、曹德骏先生的离任将导致公司第四届董事会中独 立董事占董事会成员比例低于三分之一，根据《上市公司独立董事管理 办法》和《公司章程》等有关规定，李志蜀先生、曹德骏先生的辞职将 在公司股东会选举产生新任独立董事之日生效。在新任独立董事就任前， 李志蜀先生、曹德骏先生仍将继续履行独立董事职责及其在董事会各专 门委员会中的相关职责。公司将依照法定程序尽快完成新 ...

Core Insights - The company has not developed brain-computer interface technology and equipment but is utilizing it as an auxiliary tool for its smart medical business [1] - The company aims to develop a closed-loop brain-machine interface (BMI) system based on optogenetic control to meet the needs of smart anesthesia and smart rehabilitation applications [1] Business Development - In 2022, the company established the "Brain Cognition and Smart Medical Innovation Application Laboratory" approved by Chengdu, focusing on key technologies in artificial intelligence and medical engineering [1] - The laboratory is building platforms for technology research and development, business development, and mobile application development, with plans to upgrade products in smart anesthesia assistance, IoT medical devices, integrated regional smart medical and health platforms, and rehabilitation products [1] Strategic Partnerships - The company is collaborating with the Suzhou Institute of Nano-Tech and Nano-Bionics of the Chinese Academy of Sciences to establish a brain-like intelligence and smart medical industry-university-research center [1] - This partnership aims to conduct research on key technologies and innovative applications, targeting clinical auxiliary diagnosis and treatment, clinical scientific research, and regional health and wellness applications [1] Financial Performance - In the first half of 2025, the company achieved revenue of 142 million yuan, a year-on-year decrease of 6.61% [1] - The net profit attributable to the parent company was 4 million yuan, down 24.48% year-on-year [1]

Core Viewpoint - The company is not engaged in the research and development of brain-computer interface (BCI) technology and equipment, but is utilizing BCI technology as an auxiliary tool for its smart medical business development [1] Group 1: Business Development - The company is developing a closed-loop brain-computer interface (BMI) system based on optogenetic regulation to meet the needs of smart anesthesia and smart rehabilitation applications [1] - In 2022, the company established the "Brain Cognition and Smart Medical Innovation Application Laboratory" approved by Chengdu, focusing on key technologies in artificial intelligence and medical engineering [1] Group 2: Strategic Partnerships - The company is collaborating with the Suzhou Institute of Nano-Tech and Nano-Bionics of the Chinese Academy of Sciences to build a brain-like intelligence and smart medical industry-university-research center [1] - The partnership aims to conduct research on key technologies and innovative applications, targeting clinical auxiliary diagnosis and treatment, clinical scientific research, and regional medical and health integration [1] Group 3: Product Development - The company is developing a series of products including upgraded systems for intelligent anesthesia assistance, IoT medical devices, integrated platforms for regional smart medical and health services, and upgraded rehabilitation products [1] - The focus is on creating high-end intelligent medical and rehabilitation devices, high-end wearable devices, and clinical research and auxiliary diagnosis systems and equipment as part of domestic innovation [1]

Core Insights - The company is actively developing AI intelligent agent businesses, particularly in the fields of smart education and software development [1] Group 1: Smart Education - The company, in collaboration with Chengdu Zhixue Education, has successfully implemented the Deepseek+ intelligent agent "Comprehensive Resource Management Platform" aimed at the smart education sector [1] - This platform utilizes a privatized deployment of the Deepseek AI model, tailored to the actual teaching needs of schools, enhancing training environments and optimizing experimental conditions [1] - The goal is to continuously improve teaching support capabilities and comprehensively enhance educational conditions [1] Group 2: Software Development - The company is developing two intelligent agents for the software development sector [1] - One agent is a high-performance Text2SQL data analysis tool that assists developers by converting natural language requests into SQL statements, improving development efficiency and database comprehension [1] - The second agent focuses on generating software test cases by analyzing various formats of requirement documents, extracting key testing points, and producing comprehensive test cases with human validation [1]